DUBLIN, Aug. 4, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2020 and updated its 2020 financial guidance.
"I am proud that we delivered strong financial and operational results above our expectations despite challenges arising from the COVID-19 pandemic," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "With the strong performance of Xyrem and the recent FDA approval of Xywav, we are well-positioned to ensure the durability and growth of our oxybate business with differentiated products."
"The second quarter was highlighted by the approval of Zepzelca, and our subsequent strong launch, which was accomplished within six months of closing the licensing agreement with PharmaMar," continued Mr. Cozadd. "We also innovated around the challenges of the pandemic, pivoting to a timely virtual launch of Sunosi in Germany and implementing robust measures to facilitate continued progress of our clinical development programs and regulatory filings."
"Through the issuance of $1 billion of senior notes in the second quarter, we strengthened our financial position and increased our capacity for a broader set of corporate development opportunities," concluded Mr. Cozadd. "With multiple commercial launches, the expansion of our innovative pipeline, strategic capital allocation, and projected durable revenue growth and diversification, this is a transformative year for us, and we are excited about the opportunities ahead for patients and shareholders."
The company is on track to execute up to five key launches through 2020 and 2021:
The company expects these launches to enhance the durability and long-term growth of its neuroscience business and the significant near-term and long-term value of its oncology business.
Business Updates
COVID-19
Neuroscience
Xyrem:
Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution:
Sunosi:
JZP-385
Oncology
Zepzelca™ (lurbinectedin):
Erwinaze:
JZP-458 (recombinant Erwinia asparaginase):
Defitelio:
Vyxeos:
Corporate
Financial Highlights
Three Months EndedJune 30, | Six Months EndedJune 30, | ||||||||||||||
(In thousands, except per share amounts) | 2020 | 2019 | 2020 | 2019 | |||||||||||
Total revenues | $ | 562,436 | $ | 534,133 | $ | 1,097,162 | $ | 1,042,319 | |||||||
GAAP net income (loss) | $ | 114,801 | $ | 261,898 | $ | (43,032) | $ | 347,099 | |||||||
Adjusted net income1 | $ | 207,316 | $ | 232,537 | $ | 233,149 | $ | 396,710 | |||||||
GAAP EPS | $ | 2.06 | $ | 4.56 | $ | (0.77) | $ | 6.01 | |||||||
Adjusted EPS1 | $ | 3.71 | $ | 4.05 | $ | 4.14 | $ | 6.87 |
____________________________ | |
1. | Commencing in 2020, following consultation with the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. For purposes of comparability, non-GAAP adjusted financial measures for the six months ended June 30, 2019 have been updated to reflect this change. See "Non-GAAP Financial Measures" below. |
GAAP net income for the second quarter of 2020 was $114.8 million, or $2.06 per diluted share, compared to $261.9 million, or $4.56 per diluted share, for the second quarter of 2019. On a GAAP basis, in the second quarter of 2019, the company recorded a one-time tax benefit of $112.3 million, or $1.96 per diluted share, resulting from an intra-entity intellectual property asset transfer.
Non-GAAP adjusted net income for the second quarter of 2020 was $207.3 million, or $3.71 per diluted share, compared to $232.5 million, or $4.05 per diluted share, in the second quarter of 2019. Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.
Total Revenues
Three Months EndedJune 30, | Six Months EndedJune 30, | ||||||||||||||
(In thousands) | 2020 | 2019 | 2020 | 2019 | |||||||||||
Xyrem® (sodium oxybate) oral solution | $ | 446,808 | $ | 413,212 | $ | 854,683 | $ | 781,529 | |||||||
Defitelio® (defibrotide sodium) / defibrotide | 42,714 | 46,055 | 90,146 | 87,555 | |||||||||||
Erwinaze® / Erwinase® (asparaginase Erwinia chrysanthemi) | 32,683 | 27,622 | 70,415 | 88,521 | |||||||||||
Vyxeos® (daunorubicin and cytarabine) liposome for injection | 26,568 | 31,362 | 59,288 | 60,305 | |||||||||||
Sunosi® (solriamfetol) | 8,578 | — | 10,502 | — | |||||||||||
Other | 852 | 5,172 | 3,374 | 8,844 | |||||||||||
Product sales, net | 558,203 | 523,423 | 1,088,408 | 1,026,754 | |||||||||||
Royalties and contract revenues | 4,233 | 10,710 | 8,754 | 15,565 | |||||||||||
Total revenues | $ | 562,436 | $ | 534,133 | $ | 1,097,162 | $ | 1,042,319 |
Total revenues increased 5% in the second quarter of 2020 compared to the same period in 2019. Total net product sales increased 7% in the second quarter of 2020 compared to the same period in 2019 primarily due to an increase in Xyrem, Sunosi and Erwinaze net product sales, partially offset by a decrease in Vyxeos and Defitelio net product sales.
Operating Expenses and Effective Tax Rate
Three Months EndedJune 30, | Six Months EndedJune 30, | ||||||||||||||
(In thousands, except percentages) | 2020 | 2019 | 2020 | 2019 | |||||||||||
GAAP: | |||||||||||||||
Cost of product sales | $ | 28,008 | $ | 27,676 | $ | 56,665 | $ | 61,182 | |||||||
Gross margin | 95.0 % | 94.7 % | 94.8 % | 94.0 % | |||||||||||
Selling, general and administrative | $ | 191,406 | $ | 176,014 | $ | 399,806 | $ | 343,961 | |||||||
% of total revenues | 34.0 % | 33.0 % | 36.4 % | 33.0 % | |||||||||||
Research and development | $ | 78,922 | $ | 62,384 | $ | 165,029 | $ | 122,489 | |||||||
% of total revenues | 14.0 % | 11.7 % | 15.0 % | 11.8 % | |||||||||||
Acquired in-process research and development | $ | 3,000 | $ | 2,200 | $ | 205,250 | $ | 58,200 | |||||||
Impairment charge | $ | — | $ | — | $ | 136,139 | $ | — | |||||||
Income tax provision (benefit) | $ | 54,754 | $ | (78,650) | $ | 3,467 | $ | (49,534) | |||||||
Effective tax rate | 31.9 % | (42.7) % | (9.2) % | (16.5) % | |||||||||||
Three Months EndedJune 30, | Six Months EndedJune 30, | ||||||||||||||
(In thousands, except percentages) | 2020 | 2019 | 2020 | 2019 | |||||||||||
Non-GAAP adjusted: | |||||||||||||||
Cost of product sales | $ | 26,087 | $ | 25,968 | $ | 53,071 | $ | 57,815 | |||||||
Gross margin | 95.3 % | 95.0 % | 95.1 % | 94.4 % | |||||||||||
Selling, general and administrative | $ | 170,386 | $ | 155,329 | $ | 358,190 | $ | 302,906 | |||||||
% of total revenues | 30.3 % | 29.1 % | 32.6 % | 29.1 % | |||||||||||
Research and development | $ | 71,259 | $ | 56,488 | $ | 150,981 | $ | 111,070 | |||||||
% of total revenues | 12.7 % | 10.6 % | 13.8 % | 10.7 % | |||||||||||
Acquired in-process research and development | $ | 3,000 | $ | 2,200 | $ | 205,250 | $ | 58,200 | |||||||
Income tax provision | $ | 73,085 | $ | 52,027 | $ | 77,772 | $ | 97,741 | |||||||
Effective tax rate | 25.9 % | 18.2 % | 24.9 % | 19.7 % |
Operating expenses increased over the prior year period primarily due to the following:
The effective tax rate increased over the prior year period primarily due to the following:
Cash Flow and Balance Sheet
As of June 30, 2020, cash, cash equivalents and investments were $1.7 billion, and the outstanding principal balance of the company's long-term debt was $2.4 billion. In the second quarter of 2020, the company issued $1.0 billion aggregate principal amount of 2.00% exchangeable senior notes due 2026 (2026 Notes) and used $332.9 million of the $981.4 million in net proceeds from the offering to repurchase $332.9 million aggregate principal amount of the company's 1.875% exchangeable senior notes due 2021 (2021 Notes). The remaining principal balance of the 2021 Notes was $242.1 million as of June 30, 2020. The remaining net proceeds from the issuance of the 2026 Notes will be used for general corporate purposes, including additional repurchases of the 2021 Notes. In June 2020, the company repaid a total of $500.0 million of borrowings under the company's revolving credit facility, which the company had drawn down in April 2020.
During the six months ended June 30, 2020, the company generated $455.5 million of cash from operations, made upfront and milestone payments totaling $300.0 million to PharmaMar under a license agreement and used $146.5 million to repurchase shares under the company's share repurchase program.
In the six months ended June 30, 2020, the company repurchased approximately 1.2 million ordinary shares under the company's share repurchase program at an average cost of $121.98 per ordinary share. As of June 30, 2020, the remaining amount authorized for share repurchases under the company's share repurchase program was $431.2 million.
2020 Financial Guidance
As noted above, Jazz Pharmaceuticals is updating its full year 2020 financial guidance. This guidance reflects the company's current and future expected operational performance, including the impact of COVID-19, and reflects the durability of its products, the strength of its underlying operations and the prioritization of new and ongoing value creating development projects.
(in millions) | Guidance provided as of | ||
May 5, 2020 | August 4, 2020 | ||
Revenues | $2,120 - $2,260 | $2,225 - $2,325 | |
Total net product sales | $2,105 - $2,240 | $2,210 - $2,310 | |
-Neuroscience | $1,650 - $1,740 | $1,725 - $1,800 | |
-Oncology | $420 - $510 | $445 - $525 | |
GAAP: | |||
(in millions, except per share amounts and percentages) | Guidance provided as of | ||
May 5, 2020 | August 4, 2020 | ||
Gross margin % | 94% | 94% | |
SG&A expenses | $785 - $843 | $785 - $843 | |
SG&A expenses as % of total revenues | 35% - 40% | 34% - 38% | |
R&D Expenses | $277 - $313 | $302 - $338 | |
R&D expenses as % of total revenues | 12% - 15% | 13% - 15% | |
Acquired in-process research and development expenses | $202 | $205 | |
Impairment charge | $136 | $136 | |
Effective tax rate | 22% - 29% | 19% - 26% | |
Net income per diluted share | $2.70 - $4.30 | $3.40 - $4.85 | |
Non-GAAP: | |||
(in millions, except per share amounts and percentages) | Guidance provided as of | ||
May 5, 2020 | August 4, 2020 | ||
Gross margin % | 94%1,6 | 94%1,6 | |
SG&A expenses | $700 - $7502,6 | $700 - $7502,6 | |
SG&A expenses as % of total revenues | 31% - 35% | 30% - 34% | |
R&D Expenses | $250 - $2803,6 | $275 - $3053,6 | |
R&D expenses as % of total revenues | 11% - 13% | 12% - 14% | |
Acquired in-process research and development expenses | $2024 | $2054 | |
Effective tax rate | 20% - 23%5,6 | 19% - 22%5,6 | |
Net income per diluted share | $11.25 - $12.504,6 | $11.90 - $13.004,6 |
____________________________ | |
1. | Excludes $8-$9 million of share-based compensation expense from estimated GAAP gross margin. |
2. | Excludes $85-$93 million of share-based compensation expense from estimated GAAP SG&A expenses. |
3. | Excludes $27-$33 million of share-based compensation expense from estimated GAAP R&D expenses. |
4. | Commencing in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. The impact of this change to the company's 2020 non-GAAP adjusted net income and non-GAAP adjusted EPS guidance is approximately $175 million or $3.13 per diluted share, respectively, primarily related to the post-tax impact of the $200 million upfront payment made to PharmaMar in January 2020. |
5. | Excludes the income tax effect of adjustments between GAAP reported and non-GAAP adjusted net income. |
6. | See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the table titled "Reconciliation of GAAP to Non-GAAP Adjusted 2020 Net Income Guidance" at the end of this press release. |
Conference Call Details
Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. EDT (9:30 p.m. IST) to provide a business and financial update and discuss its 2020 second quarter results. The live webcast may be accessed from the Investors section of the company's website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing +1 855 353 7924 in the U.S., or +1 503 343 6056 outside the U.S., and entering passcode 2644219.
A replay of the conference call will be available through August 11, 2020 by dialing +1 855 859 2056 in the U.S., or +1 404 537 3406 outside the U.S., and entering passcode 2644219. An archived version of the webcast will be available for at least one week in the Investors section of the company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases - often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
Non-GAAP Financial Measures
To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this press release and the accompanying tables. In particular, the company presents non-GAAP adjusted net income (and the related per share measure) and its line item components, as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP adjusted net income (and the related per share measure) and its line item components exclude from GAAP reported net income (loss) (and the related per share measure) and its line item components certain items, as detailed in the reconciliation tables that follow, and in the case of non-GAAP adjusted net income (and the related per share measure), adjust for the income tax effect of non-GAAP adjustments and the income tax benefit related to an intra-entity intellectual property asset transfer. In this regard, the components of non-GAAP adjusted net income, including non-GAAP cost of product sales, non-GAAP SG&A expenses and non-GAAP R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income measure.
The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals' management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. For example, commencing in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. For purposes of comparability, non-GAAP adjusted financial measures for the six months ended June 30, 2019 have been updated to reflect this change. Accordingly, such payments are not excluded from its non-GAAP financial measures for the three and six months ended June 30, 2020 and 2019, or from 2020 non-GAAP adjusted net income guidance and non-GAAP adjusted net income per diluted share guidance as detailed in the reconciliation tables that follow. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future financial and operating results, including the company's updated 2020 financial guidance; the company's belief that it is well-positioned to ensure the durability and growth of its oxybate business with differentiated products and that 2020 is a transformative year for the company with multiple commercial launches, the expansion of its innovative pipeline, strategic capital allocation and projected revenue growth and diversification; the company's expectation that its 2020 and 2021 product launches will enhance the durability and long-term growth of its neuroscience business and the significant near- and long-term value of its oncology business; the company's expected clinical development and regulatory milestones and the timing thereof, including with respect to JZP-458, Xywav in idiopathic hypersomnia and defibrotide for the prevention of acute graft-versus-host disease; the company's expectation of interquarter variability in Erwinaze net product sales due to timing and availability of supply and its expectation of distributing Erwinaze supply through the first half of 2021; and other statements that are not historical facts. These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the ultimate duration and severity of the COVID-19 pandemic and resulting global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the company's business operations and financial results; maintaining or increasing sales of and revenue from Xyrem and other key marketed products; effectively launching and commercializing the company's other products and product candidates; the time-consuming and uncertain regulatory approval process, including the risk that the company's planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients such as those being experienced, and expected to continue to be experienced, by the company as a result of the effects of the COVID-19 pandemic; protecting and enhancing the company's intellectual property rights; delays or problems in the supply or manufacture of the company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements; government investigations, legal proceedings and other actions; obtaining and maintaining adequate coverage and reimbursement for the company's products; identifying and acquiring, in-licensing or developing additional products or product candidates, financing these transactions and successfully integrating acquired product candidates, products and businesses; the company's ability to realize the anticipated benefits of its collaborations with third parties for the development of product candidates; the company's ability to achieve expected future financial performance and results and the uncertainty of future tax and other provisions and estimates; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc'sSecurities and Exchange Commission filings and reports (Commission File No. 001-33500), including the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and future filings and reports by the company, including the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. In addition, while the company expects the COVID-19 pandemic to continue to adversely affect its business operations and financial results, the extent of the impact on the company's ability to generate sales of and revenues from its approved products, execute on new product launches, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration and severity of the pandemic, governmental "stay-at-home" orders and travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Ireland and other countries, and the effectiveness of actions taken globally to contain and treat the disease. Moreover, other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.
JAZZ PHARMACEUTICALS PLC | |||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) | |||||||||||||||
(In thousands, except per share amounts) | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months EndedJune 30, | Six Months EndedJune 30, | ||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||
Revenues: | |||||||||||||||
Product sales, net | $ | 558,203 | $ | 523,423 | $ | 1,088,408 | $ | 1,026,754 | |||||||
Royalties and contract revenues | 4,233 | 10,710 | 8,754 | 15,565 | |||||||||||
Total revenues | 562,436 | 534,133 | 1,097,162 | 1,042,319 | |||||||||||
Operating expenses: | |||||||||||||||
Cost of product sales (excluding amortization of acquired developed technologies) | 28,008 | 27,676 | 56,665 | 61,182 | |||||||||||
Selling, general and administrative | 191,406 | 176,014 | 399,806 | 343,961 | |||||||||||
Research and development | 78,922 | 62,384 | 165,029 | 122,489 | |||||||||||
Intangible asset amortization | 62,974 | 61,576 | 125,821 | 118,461 | |||||||||||
Acquired in-process research and development | 3,000 | 2,200 | 205,250 | 58,200 | |||||||||||
Impairment charge | — | — | 136,139 | — | |||||||||||
Total operating expenses | 364,310 | 329,850 | 1,088,710 | 704,293 | |||||||||||
Income from operations | 198,126 | 204,283 | 8,452 | 338,026 | |||||||||||
Interest expense, net | (26,210) | (18,234) | (44,706) | (36,156) | |||||||||||
Foreign exchange loss | (464) | (1,933) | (1,596) | (2,544) | |||||||||||
Income (loss) before income tax provision (benefit) and equity in loss of investees | 171,452 | 184,116 | (37,850) | 299,326 | |||||||||||
Income tax provision (benefit) | 54,754 | (78,650) | 3,467 | (49,534) | |||||||||||
Equity in loss of investees | 1,897 | 868 | 1,715 | 1,761 | |||||||||||
Net income (loss) | $ | 114,801 | $ | 261,898 | $ | (43,032) | $ | 347,099 | |||||||
Net income (loss) per ordinary share: | |||||||||||||||
Basic | $ | 2.07 | $ | 4.62 | $ | (0.77) | $ | 6.09 | |||||||
Diluted | $ | 2.06 | $ | 4.56 | $ | (0.77) | $ | 6.01 | |||||||
Weighted-average ordinary shares used in per share calculations - basic | 55,413 | 56,707 | 55,684 | 56,955 | |||||||||||
Weighted-average ordinary shares used in per share calculations - diluted | 55,864 | 57,427 | 55,684 | 57,753 |
JAZZ PHARMACEUTICALS PLC | |||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
(In thousands) | |||||||
(Unaudited) | |||||||
June 30, 2020 | December 31, 2019 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 786,082 | $ | 637,344 | |||
Investments | 910,000 | 440,000 | |||||
Accounts receivable, net of allowances | 351,920 | 355,987 | |||||
Inventories | 92,534 | 78,608 | |||||
Prepaid expenses | 49,109 | 39,434 | |||||
Other current assets | 112,701 | 78,895 | |||||
Total current assets | 2,302,346 | 1,630,268 | |||||
Property, plant and equipment, net | 128,259 | 131,506 | |||||
Operating lease assets | 133,179 | 139,385 | |||||
Intangible assets, net | 2,286,126 | 2,440,977 | |||||
Goodwill | 918,021 | 920,018 | |||||
Deferred tax assets, net | 243,395 | 221,403 | |||||
Deferred financing costs | 6,347 | 7,426 | |||||
Other non-current assets | 48,828 | 47,914 | |||||
Total assets | $ | 6,066,501 | $ | 5,538,897 | |||
LIABILITIES AND SHAREHOLDERS' EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 50,043 | $ | 45,732 | |||
Accrued liabilities | 266,918 | 269,686 | |||||
Current portion of long-term debt | 33,387 | 33,387 | |||||
Income taxes payable | 55,979 | 10,965 | |||||
Deferred revenue | 3,633 | 4,720 | |||||
Total current liabilities | 409,960 | 364,490 | |||||
Deferred revenue, non-current | 3,588 | 4,861 | |||||
Long-term debt, less current portion | 2,069,669 | 1,573,870 | |||||
Operating lease liabilities, less current portion | 144,264 | 151,226 | |||||
Deferred tax liabilities, net | 162,376 | 224,095 | |||||
Other non-current liabilities | 134,839 | 109,374 | |||||
Total shareholders' equity | 3,141,805 | 3,110,981 | |||||
Total liabilities and shareholders' equity | $ | 6,066,501 | $ | 5,538,897 |
JAZZ PHARMACEUTICALS PLC | |||||||
SUMMARY OF CASH FLOWS | |||||||
(In thousands) | |||||||
(Unaudited) | |||||||
Six Months EndedJune 30, | |||||||
2020 | 2019 | ||||||
Net cash provided by operating activities | $ | 455,488 | $ | 351,100 | |||
Net cash provided by (used in) investing activities | (801,245) | 163,414 | |||||
Net cash provided by (used in) financing activities | 494,851 | (186,502) | |||||
Effect of exchange rates on cash and cash equivalents | (356) | 105 | |||||
Net increase in cash and cash equivalents | $ | 148,738 | $ | 328,117 |
JAZZ PHARMACEUTICALS PLC | |||||||||||||||
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION | |||||||||||||||
(In thousands, except per share amounts) | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months EndedJune 30, | Six Months EndedJune 30, | ||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||
GAAP reported net income (loss) | $ | 114,801 | $ | 261,898 | $ | (43,032) | $ | 347,099 | |||||||
Intangible asset amortization | 62,974 | 61,576 | 125,821 | 118,461 | |||||||||||
Share-based compensation expense | 30,604 | 28,289 | 59,258 | 55,841 | |||||||||||
Impairment charge (a) | — | — | 136,139 | — | |||||||||||
Non-cash interest expense (b) | 12,793 | 11,451 | 24,793 | 22,584 | |||||||||||
Loss on extinguishment of debt | 4,475 | — | 4,475 | — | |||||||||||
Income tax effect of above adjustments | (18,331) | (18,403) | (74,305) | (35,001) | |||||||||||
Income tax benefit related to intra-entity intellectual property asset transfer | — | (112,274) | — | (112,274) | |||||||||||
Non-GAAP adjusted net income | $ | 207,316 | $ | 232,537 | $ | 233,149 | $ | 396,710 | |||||||
GAAP reported net income (loss) per diluted share | $ | 2.06 | $ | 4.56 | $ | (0.77) | $ | 6.01 | |||||||
Non-GAAP adjusted net income per diluted share | $ | 3.71 | $ | 4.05 | $ | 4.14 | $ | 6.87 | |||||||
Weighted-average ordinary shares used in diluted per share calculations - GAAP | 55,864 | 57,427 | 55,684 | 57,753 | |||||||||||
Weighted-average ordinary shares used in diluted per share calculations - non-GAAP | 55,864 | 57,427 | 56,328 | 57,753 |
________________________________________________ | |
Explanation of Adjustments and Certain Line Items: | |
(a) | Impairment charge related to the company's decision to stop enrollment in its Phase 3 clinical study of defibrotide for the prevention of veno-occlusive disease due to a determination by an Independent Data Monitoring Committee that it is highly unlikely that the study will reach its primary endpoint. |
(b) | Non-cash interest expense associated with debt discount and debt issuance costs. |
JAZZ PHARMACEUTICALS PLC | |||||||||||||||||||||||||||||
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION | |||||||||||||||||||||||||||||
CERTAIN LINE ITEMS - FOR THE THREE MONTHS ENDED JUNE 30, 2020 and 2019 | |||||||||||||||||||||||||||||
(In thousands, except percentages) | |||||||||||||||||||||||||||||
(Unaudited) | |||||||||||||||||||||||||||||
Three months ended June 30, 2020 | |||||||||||||||||||||||||||||
Cost of product sales | Gross margin | Selling, general and administrative | Research and development | Intangible asset amortization | Interest expense, net | Income tax provision | Effective tax rate | ||||||||||||||||||||||
GAAP Reported | $ | 28,008 | 95.0 % | $ | 191,406 | $ | 78,922 | $ | 62,974 | $ | 26,210 | $ | 54,754 | 31.9 % | |||||||||||||||
Non-GAAP Adjustments: | |||||||||||||||||||||||||||||
Intangible asset amortization | — | — | — | — | (62,974) | — | — | — | |||||||||||||||||||||
Share-based compensation expense | (1,921) | 0.3 | (21,020) | (7,663) | — | — | — | — | |||||||||||||||||||||
Non-cash interest expense | — | — | — | — | — | (12,793) | — | — | |||||||||||||||||||||
Loss on extinguishment of debt | — | — | — | — | — | (4,475) | — | — | |||||||||||||||||||||
Income tax effect of above adjustments | — | — | — | — | — | — | 18,331 | (6.0) | |||||||||||||||||||||
Total of Non-GAAP adjustments | (1,921) | 0.3 | (21,020) | (7,663) | (62,974) | (17,268) | 18,331 | (6.0) | |||||||||||||||||||||
Non-GAAP Adjusted | $ | 26,087 | 95.3 % | $ | 170,386 | $ | 71,259 | $ | — | $ | 8,942 | $ | 73,085 | 25.9 % | |||||||||||||||
Three months ended June 30, 2019 | |||||||||||||||||||||||||||||
Cost of product sales | Gross margin | Selling, general and administrative | Research and development | Intangible asset amortization | Interest expense, net | Income tax provision (benefit) | Effective tax rate | ||||||||||||||||||||||
GAAP Reported | $ | 27,676 | 94.7 % | $ | 176,014 | $ | 62,384 | $ | 61,576 | $ | 18,234 | $ | (78,650) | (42.7) % | |||||||||||||||
Non-GAAP Adjustments: | |||||||||||||||||||||||||||||
Intangible asset amortization | — | — | — | — | (61,576) | — | — | — | |||||||||||||||||||||
Share-based compensation expense | (1,708) | 0.3 | (20,685) | (5,896) | — | — | — | — | |||||||||||||||||||||
Non-cash interest expense | — | — | — | — | — | (11,451) | — | — | |||||||||||||||||||||
Income tax effect of above adjustments | — | — | — | — | — | — | 18,403 | (0.1) | |||||||||||||||||||||
Income tax benefit related to intra-entity intellectual property asset transfer | — | — | — | — | — | — | 112,274 | 61.0 | |||||||||||||||||||||
Total of Non-GAAP adjustments | (1,708) | 0.3 | (20,685) | (5,896) | (61,576) | (11,451) | 130,677 | 60.9 | |||||||||||||||||||||
Non-GAAP Adjusted | $ | 25,968 | 95.0 % | $ | 155,329 | $ | 56,488 | $ | — | $ | 6,783 | $ | 52,027 | 18.2 % |
JAZZ PHARMACEUTICALS PLC | |||||||||||||||||||||||||||||||||
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION | |||||||||||||||||||||||||||||||||
CERTAIN LINE ITEMS - FOR THE SIX MONTHS ENDED JUNE 30, 2020 and 2019 | |||||||||||||||||||||||||||||||||
(In thousands) | |||||||||||||||||||||||||||||||||
(Unaudited) | |||||||||||||||||||||||||||||||||
Six months ended June 30, 2020 | |||||||||||||||||||||||||||||||||
Cost of product sales | Gross margin | Selling, general and administrative | Research and development | Intangible asset amortization | Impairment charge | Interest expense, net | Income tax provision | Effective tax rate | |||||||||||||||||||||||||
GAAP Reported | $ | 56,665 | 94.8 % | $ | 399,806 | $ | 165,029 | $ | 125,821 | $ | 136,139 | $ | 44,706 | $ | 3,467 | (9.2) % | |||||||||||||||||
Non-GAAP Adjustments: | |||||||||||||||||||||||||||||||||
Intangible asset amortization | — | — | — | — | (125,821) | — | — | — | — | ||||||||||||||||||||||||
Share-based compensation expense | (3,594) | 0.3 | (41,616) | (14,048) | — | — | — | — | — | ||||||||||||||||||||||||
Impairment charges | — | — | — | — | — | (136,139) | — | — | — | ||||||||||||||||||||||||
Non-cash interest expense | — | — | — | — | — | — | (24,793) | — | — | ||||||||||||||||||||||||
Loss on extinguishment of debt | — | — | — | — | — | — | (4,475) | — | — | ||||||||||||||||||||||||
Income tax effect of above adjustments | — | — | — | — | — | — | — | 74,305 | 34.1 | ||||||||||||||||||||||||
Total of Non-GAAP adjustments | (3,594) | 0.3 | (41,616) | (14,048) | (125,821) | (136,139) | (29,268) | 74,305 | 34.1 | ||||||||||||||||||||||||
Non-GAAP Adjusted | $ | 53,071 | 95.1 % | $ | 358,190 | $ | 150,981 | $ | — | $ | — | $ | 15,438 | $ | 77,772 | 24.9 % | |||||||||||||||||
Six months ended June 30, 2019 | |||||||||||||||||||||||||||||||||
Cost of product sales | Gross margin | Selling, general and administrative | Research and development | Intangible asset amortization | Interest expense, net | Income tax provision (benefit) | Effective tax rate | ||||||||||||||||||||||||||
GAAP Reported | $ | 61,182 | 94.0 % | $ | 343,961 | $ | 122,489 | $ | 118,461 | $ | 36,156 | $ | (49,534) | (16.5) % | |||||||||||||||||||
Non-GAAP Adjustments: | |||||||||||||||||||||||||||||||||
Intangible asset amortization | — | — | — | — | (118,461) | — | — | — | |||||||||||||||||||||||||
Share-based compensation expense | (3,367) | 0.4 | (41,055) | (11,419) | — | — | — | — | |||||||||||||||||||||||||
Non-cash interest expense | — | — | — | — | — | (22,584) | — | — | |||||||||||||||||||||||||
Income tax effect of above adjustments | — | — | — | — | — | — | 35,001 | (1.3) | |||||||||||||||||||||||||
Income tax benefit related to intra-entity intellectual property asset transfer | — | — | — | — | — | — | 112,274 | 37.5 | |||||||||||||||||||||||||
Total of Non-GAAP adjustments | (3,367) | 0.4 | (41,055) | (11,419) | (118,461) | (22,584) | 147,275 | 36.2 | |||||||||||||||||||||||||
Non-GAAP Adjusted | $ | 57,815 | 94.4 % | $ | 302,906 | $ | 111,070 | $ | — | $ | 13,572 | $ | 97,741 | 19.7 % |
JAZZ PHARMACEUTICALS PLC | ||
RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2020 NET INCOME GUIDANCE | ||
(In millions, except per share amounts) | ||
(Unaudited) | ||
GAAP net income | $190 - $270 | |
Intangible asset amortization | 250 - 270 | |
Share-based compensation expense | 120 -135 | |
Impairment charge | 136 | |
Loss on extinguishment of debt | 4 | |
Non-cash interest expense | 50 - 60 | |
Income tax effect of adjustments | (105) - (115) | |
Non-GAAP adjusted net income | $670 - $730 | |
GAAP net income per diluted share | $3.40 - $4.85 | |
Non-GAAP adjusted net income per diluted share | $11.90 - $13.00 | |
Weighted-average ordinary shares used in per share calculations | 56 |
Contacts:
Investors:Kathee LittrellVice President, Investor RelationsJazz Pharmaceuticals plcIreland, +353 1 634 7887U.S., +1 650 496 2717
Media:Jacqueline KirbyVice President, Corporate Affairs & Government RelationsJazz Pharmaceuticals plcIreland, +353 1 697 2141U.S., +1 215 867 4910
View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-second-quarter-2020-financial-results-301106004.html
SOURCE Jazz Pharmaceuticals plc